Pi-Cardia has developed a unique non-implant based solutions for treating valve calcification.

Pi-Cardia’s lead product, the Leaflex™ catheter system, is easily delivered and positioned on the valve, to then score the calcification mechanically at multiple locations, restoring leaflets flexibility and improving valve hemodynamic. The Leaflex™ catheter is aimed to be a cost-effective standalone treatment or a preparatory step for improving the outcome of valve implantation in heavily calcified aortic valves, bicuspid valves and calcified mitral valves. ShortCut™, a dedicated transcatheter leaflet splitting device, is the second product under development.

Atlante Ventures invested in Pi-Cardia in 2015 and participated in other follow-on rounds.